{"nct_id":"NCT03898180","title":"Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)","status":"COMPLETED","status_verified_date":"2025-05","start_date":"2019-05-06","start_date_type":"ACTUAL","primary_completion_date":"2021-07-26","primary_completion_date_type":"ACTUAL","completion_date":"2024-05-20","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}